New Dual-Target CAR t therapy takes on Hard-to-Treat kidney cancer
NCT ID NCT07564232
First seen May 11, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This early-phase study tests a new treatment called LNK001 for people with advanced or metastatic clear cell renal cell carcinoma (a type of kidney cancer) that has not responded to prior therapies. LNK001 is a type of immunotherapy where a patient's own immune cells are engineered to recognize and attack cancer cells using two specific targets (ENPP3 and CAIX) to improve precision. The study aims to find the safest dose and see if it can help control the disease in 40 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.